Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + Chemotherapy in Older FLT3-Mutated AML (CALGB 11001)
NCT01253070Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Apr 2011; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01253070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253070.